Application of lactobacillus reuteri and / or metabolite thereof
Lactobacillus reuteri TCI979 and its metabolites improve antioxidant capacity and mitochondrial activity, slow down muscle loss and cell aging, thus solving the problems of muscle loss and cell aging and achieving improved muscle endurance and enhanced telomerase activity.
Patent Information
- Application Number
- CN202510462242.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-04-19
- Filing Date
- 2025-04-14
- Publication Date
- 2025-10-24
AI Technical Summary
Existing technologies have failed to effectively address issues such as muscle loss, muscle endurance improvement, and cell aging, especially under the influence of factors such as oxidative stress and apoptosis.
Using Lactobacillus reuteri TCI979 and its metabolites, this study reduced malondialdehyde levels in the blood, increased total antioxidant capacity and sulfur-containing compound content, inhibited reactive oxygen species, reduced cell apoptosis, and enhanced mitochondrial and telomerase activity in muscle cells.
It significantly slows down muscle loss, improves muscle endurance, slows down cell aging, restores mitochondrial activity, inhibits cell apoptosis and telomere shortening, and enhances the body's antioxidant capacity.
Smart Images

Figure CN120827577A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present invention relates to a Lactobacillus reuteri, in particular to the use of a Lactobacillus reuteri and / or metabolites thereof for the manufacture of a composition for slowing down muscle loss, for enhancing muscle endurance or for slowing down cell aging. BACKGROUND
[0002] Lactobacillus reuteri is an important species of lactic acid bacteria, which is usually used to improve the intestinal flora of mammals, antagonize the colonization of other harmful bacteria in the intestine, and is a potential probiotic. SUMMARY
[0003] The present invention provides a Lactobacillus reuteri and / or metabolites thereof, wherein the Lactobacillus reuteri is Lactobacillus reuteri TCI979 with accession number DSM34539.
[0004] In some embodiments, the Lactobacillus reuteri and / or metabolites thereof are used for the manufacture of a composition for slowing down muscle loss.
[0005] In some embodiments, the Lactobacillus reuteri and / or metabolites thereof are used for the manufacture of a composition for enhancing muscle endurance.
[0006] In some embodiments, the Lactobacillus reuteri and / or metabolites thereof are used for the manufacture of a composition for slowing down cell aging.
[0007] In some embodiments, the Lactobacillus reuteri can reduce the content of malondialdehyde in blood.
[0008] In some embodiments, the Lactobacillus reuteri can enhance the total antioxidant capacity (TAC) or the content of f-Thiols in blood.
[0009] In some embodiments, the Lactobacillus reuteri can inhibit the content of reactive oxygen species.
[0010] In some embodiments, the Lactobacillus reuteri can reduce apoptosis.
[0011] In some embodiments, the Lactobacillus reuteri can enhance the mitochondrial activity of muscle cells.
[0012] In some embodiments, the Lactobacillus reuteri can slow down the rate of telomere shortening.
[0013] In some embodiments, the Lactobacillus reuteri can enhance the activity of telomerase.
[0014] In summary, the Lactobacillus reuteri and / or its metabolite of any embodiment can reduce the level of malondialdehyde in blood, increase the total antioxidant capacity or the level of sulfur compounds in blood, inhibit the level of reactive oxygen species or reduce cell apoptosis, thereby slowing down muscle loss. The Lactobacillus reuteri and / or its metabolite of any embodiment can increase muscle cell mitochondrial activity, reduce the level of malondialdehyde in blood, increase the total antioxidant capacity or the level of sulfur compounds in blood or inhibit the level of reactive oxygen species, thereby increasing muscle endurance. The Lactobacillus reuteri and / or its metabolite of any embodiment can slow down the rate of telomere shortening, increase the activity of telomerase or inhibit the level of reactive oxygen species, thereby slowing down cell aging. BRIEF DESCRIPTION OF DRAWINGS
[0015] Figure 1 is a graph of the results of the Lactobacillus reuteri in the inhibition of ROS test.
[0016] Figure 2 is a graph of the results of the Lactobacillus reuteri in the avoidance of cell apoptosis test.
[0017] Figure 3 is a graph of the results of the Lactobacillus reuteri in the inhibition of mitochondrial activity reduction test.
[0018] Figure 4 is a graph of the results of the Lactobacillus reuteri in the increase of telomerase activity test.
[0019] Figure 5 is a graph of the results of the Lactobacillus reuteri in the cell size change test.
[0020] Figure 6 is a graph of the results of the Lactobacillus reuteri in the cell size change test under natural aging.
[0021] Figure 7 is a graph of the results of the Lactobacillus reuteri in the cell size change test under external oxidative damage.
[0022] Figure 8 is a graph of the results of the blood MDA concentration change in the human experiment.
[0023] Figure 9 is a graph of the results of the total antioxidant capacity change in the human experiment.
[0024] Figure 10 is a graph of the results of the blood sulfur compound concentration change in the human experiment.
[0025] Figure 11 is a graph of the results of the average upper limb muscle endurance change in the human experiment.
[0026] Figure 12 is a graph of the results of the average lower limb muscle endurance change in the human experiment.
[0027] Preservation of biological material
[0028] Limosilactobacillus reuteri TCI979 was deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Germany) on February 17, 2023, under the accession number DSM34539, and was named Limosilactobacillus reuteri TCI979. DETAILED DESCRIPTION
[0029] Limosilactobacillus reuteri TCI979 was deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH under the accession number DSM34539. In some embodiments, Limosilactobacillus reuteri TCI979 is a strain isolated from Wolongtan, Guizhou, China.
[0030] The Limosilactobacillus reuteri of the present application, also known as Limosilactobacillus reuteri TCI979, is commonly found in the intestines, mouth, and stomach of humans and animals, and can also be present in fermented foods (such as yogurt, pickles) and dairy products. Here, Limosilactobacillus reuteri TCI979 is a facultative anaerobic, gram-positive bacterium, but prefers low-oxygen or anaerobic environments. It appears roughly elongated, rod-shaped, with curved ends, and is about 0.5 to 0.8 microns wide and 2 to 8 microns long. It lacks flagella and has no active movement, does not produce spores, and generally does not form a capsule. Its main energy source is carbohydrates such as monosaccharides (such as glucose, fructose) and disaccharides (such as lactose) as carbon sources, which are metabolized through the phosphoketolase pathway to produce metabolites such as lactic acid, ethanol, acetic acid, and carbon dioxide. Limosilactobacillus reuteri can metabolize glycerol to produce reuterin, a non-protein antibacterial substance that can effectively inhibit the growth of harmful bacteria and is harmless to animals.
[0031] In some embodiments, Limosilactobacillus reuteri TCI979 and / or its metabolites have the effect of slowing muscle loss. In other words, Limosilactobacillus reuteri TCI979 and / or its metabolites are suitable for use in the preparation of a muscle loss slowing composition.
[0032] In some embodiments, Limosilactobacillus reuteri TCI979 and / or its metabolites have the effect of improving muscle endurance. In other words, Limosilactobacillus reuteri and / or its metabolites are used for the use of preparing a muscle endurance improving composition.
[0033] In some embodiments, Limosilactobacillus reuteri TCI979 and / or its metabolites have the effect of slowing cell aging. In other words, Limosilactobacillus reuteri or its metabolites are used for the use of preparing a cell aging slowing composition.
[0034] In some embodiments, the Lactobacillus reuteri can reduce the level of malondialdehyde (MDA) in blood. MDA is generally formed due to lipid peroxidation. MDA is highly reactive in the body and can bind to DNA or proteins to destroy normal cell development. Generally, the higher the level of MDA in the body, the worse the antioxidant capacity. Studies have shown that the level of MDA in muscle significantly increases with age and gradually increases with the decrease in muscle mass.
[0035] In some embodiments, the Lactobacillus reuteri can improve the total antioxidant capacity (TAC). TAC refers to the ability of the body to reduce oxidants. The higher the TAC, the better the antioxidant capacity in the body, and the better the muscle strength and muscle mass.
[0036] In some embodiments, the Lactobacillus reuteri can improve the level of f-thiols in blood. Here, f-thiols refer to sulfur-containing compounds in blood. F-thiols can act as free radical scavengers to directly neutralize free radicals or reduce oxidative stress by regulating redox signaling pathways (such as increasing glutathione reductase activity) to help maintain normal cell functions, including energy metabolism, DNA repair, and protein synthesis, to improve muscle strength and mass.
[0037] In some embodiments, the Lactobacillus reuteri can inhibit the level of reactive oxygen species.
[0038] In some embodiments, the Lactobacillus reuteri can reduce apoptosis. Apoptosis is a natural death phenomenon of cells under genetic regulation after environmental stimulation, and is also called programmed cell death. It is different from cell necrosis. Under normal circumstances, any abnormality that occurs during cell formation will be eliminated through apoptosis. For example, the growth of cancer cells in the body into tumors will be inhibited by apoptosis.
[0039] In some embodiments, the Lactobacillus reuteri can improve the mitochondrial activity of muscle cells.
[0040] In some embodiments, the Lactobacillus reuteri can slow down the rate of telomere shortening. In some embodiments, the Lactobacillus reuteri can enhance telomerase activity. Telomeres refer to highly repetitive DNA sequences or protein complexes located at the ends of chromosomes, which are essential for maintaining the integrity and stability of chromosomes. That is, when telomere length shortens with cell division, this shortening phenomenon easily causes cell aging or disease, and telomerase can more effectively lengthen and maintain the length of telomeres, slowing down the rate of telomere shortening.
[0041] In some embodiments, the specific amount of Lactobacillus reuteri is 100 mg / day.
[0042] In some embodiments, the aforementioned composition comprises a specific amount of Lactobacillus reuteri or its metabolite. That is, the amount of Lactobacillus reuteri TCI979 used is 100 mg / day. Specifically, assuming that one serving of the composition is administered daily and the Lactobacillus reuteri is a dry powder, the composition then comprises at least 100 mg of Lactobacillus reuteri.
[0043] In some embodiments, the aforementioned composition can be a health product, a food product, or a food additive for non-medical purposes. In other words, the health product, the food product, or the food additive comprises a specific amount of Lactobacillus reuteri.
[0044] In some embodiments, the aforementioned health product, food product, or food additive can further comprise a food industry acceptable carrier. For example, the food industry acceptable carrier can comprise one or more of the following agents: solvents, buffers, emulsifiers, suspending agents, decomposers, disintegrating agents, dispersing agents, binding agents, excipients, stabilizing agents, chelating agents, diluents, gelling agents, preservatives, wetting agents, lubricants, absorption delaying agents, liposomes, and the like. The selection and amounts of these agents are within the ordinary skill and competence of those in the art.
[0045] In some embodiments, the aforementioned food industry acceptable carrier comprises a solvent selected from the group consisting of water, normal saline, phosphate buffered saline (PBS), and aqueous solution containing alcohol.
[0046] In some embodiments, the food product can be, but is not limited to, beverages, fermented foods, bakery products, health foods for non-medical purposes, and dietary supplements.
[0047] Example 1: Isolation and identification of strains
[0048] First, an appropriate amount of water from Wolongtan Lake in Guizhou, China, was added to liquid Lactobacilli MRS broth (BD Difco™ Lactobacilli MRS Broth) and cultured at 37°C in an anaerobic environment (i.e., an oxygen concentration of 1% by volume) for 24 hours to form a bacterial suspension. Next, the bacterial suspension was serially diluted and plated onto solid Lactobacilli MRS broth (BD Difco™ Lactobacilli MRS Broth with 1.5% agar) and cultured at 37°C in an anaerobic environment (i.e., an oxygen concentration of 1% by volume) until colonies formed on the plate. One colony was then selected for subsequent testing.
[0049] Next, the bacterial strain from the colony was identified. The 16S ribosomal gene (16S rDNA) sequence of this isolated strain (i.e., SEQ ID NO: 1) was obtained through polymerase chain reaction (PCR). The total length of the gene sequence was 1,050. Next, using the National Center for Biotechnology Information (NCBI) website, the gene sequence was compared with the 16S rDNA sequences of other Lactobacillus species. The similarity of the 16S rDNA sequences is shown in Table 1 below. The 16S rDNA sequence of this isolated strain showed the highest similarity to that of Lactobacillus reuteri (Accession No. NBRC 15892).
[0050] Table 1
[0051]
[0052]
[0053] The 16S rDNA sequence of the strain isolated from Wolongtan Lake in Guizhou, China, has a high similarity of 99.42% with that of Lactobacillus reuteri. Therefore, the strain was named Lactobacillus reuteri TCI979.
[0054] Example 2: Preservation and cultivation experiment of Lactobacillus reuteri
[0055] The isolated Lactobacillus reuteri was cultured at a 1% bacterial count (approximately 1×10 4 CFU / mL) were inoculated into MRS medium (BD Difco TM The cells were then cultured in Lactobacilli MRS Broth (1% (v / v)) at 37°C under anaerobic conditions for 24 hours to form a TCI979 bacterial suspension.
[0056] The TCI979 bacterial solution was centrifuged at 5000 rpm for 20 minutes to separate the supernatant and the Lactobacillus reuteri bacteria. The supernatant was filtered through a 0.2 μm filter, and the resulting filtrate was the TCI979 sample (i.e., the TCI979 sample contained Lactobacillus reuteri metabolic products).
[0057] The TCI979 bacterial solution was added to 5% (W / W) soy milk powder, 5% (W / W) trehalose, 10% (W / W) sorbitol, and 20% (W / W) indigestible malt dextrin, mixed evenly, freeze-dried, and ground into powder to form the TCI979 bacterial powder.
[0058] Example 3: Active oxygen content test
[0059] This test used hydrogen peroxide (H2O2) to simulate the situation in which cells are damaged by external oxidation. The change in the active oxygen content of human peripheral blood mononuclear cells treated with the TCI979 sample was observed to determine whether the sample could help the cells resist oxidative damage. In this test, the probe DCFH-DA was used in combination with flow cytometry to determine the change in the active oxygen content of human peripheral blood mononuclear cells treated with the TCI979 sample.
[0060] 3-1. Materials and instruments:
[0061] Cells: Human peripheral blood mononuclear cells (PBMC cells, purchased from lifeline, model HC-002).
[0062] Culture medium: RPMI 1640 (Roswell Park Memorial Institute, purchased from Gibco), supplemented with 10% FBS (Fetal Bovine Serum, purchased from Gibco) and 1% antibiotic-antimycotic (purchased from Gibco).
[0063] PBS buffer and DPBS buffer (purchased from Gibco).
[0064] Hydrogen peroxide H2O2 (purchased from Sigma).
[0065] 2,7-dichloro-dihydro-fluorescein diacetate (DCFH-DA) (purchased from Sigma / SI-D6883-50MG). The DCFH-DA was dissolved in DMSO before use to dilute it to a concentration of 5 μg / mL DCFH-DA solution.
[0066] Flow cytometer (purchased from BD Company, model Accuri TM C6 Plus).
[0067] 3-2. Test procedure:
[0068] First, 1 x 10 5 PBMC cells were taken to a six-well cell culture dish containing 2 mL of medium per well, and incubated at 37°C, 5% CO2 for 24 hours.
[0069] After the PBMC cells in each well were in a suspended state in the cell culture dish, the PBMC cells were separated into a blank group, a control group, and an experimental group.
[0070] Blank group: only medium was added, and was treated at 37°C for 2 hours.
[0071] Control group: medium was added, and was treated at 37°C for 1 hour, then 1 mM hydrogen peroxide was added, and was treated at 37°C for another 1 hour.
[0072] Experimental group: medium containing 0.125% TCI979 sample prepared in Example 2 was added, and was treated at 37°C for 1 hour, then 1 mM hydrogen peroxide was added, and was treated at 37°C for another 1 hour.
[0073] Next, 5 μg / mL DCFH-DA solution was added to each group of cells, and was treated at 37°C for 15 minutes.
[0074] After the cells in each group were moved to a 1.5 mL centrifuge tube, centrifugation (400 x g) was performed for 5 minutes, the supernatant was removed, and washing with 1X PBS buffer was performed, followed by centrifugation (400 x g) for 5 minutes. After centrifugation, the supernatant was removed, 200 μL of 1X DPBS buffer was added to each tube to resuspend the PBMC cells, and a cell solution to be tested was formed.
[0075] The fluorescence signal of DCFH-DA in each group of cell solutions to be tested was detected using a flow cytometer (excitation light: 450-490 nm; scattered light: 510-550 nm). The fluorescence intensity of PBMC cells treated with DCFH-DA can reflect the content of intracellular reactive oxygen species (ROS), and can be converted into a relative numerical value.
[0076] 3-3. Test results:
[0077] It should be particularly noted that, Figure 1The results are shown in relative fold, i.e. the quantification results of the experimental groups are converted into the performance relative to the blank group by taking the quantification results of the blank group as 100. Among them, Student T-Test is used to analyze whether there is a statistically significant difference. In the figure, "#" represents that the p value is less than 0.05 relative to the blank group, "##" represents that the p value is less than 0.01 relative to the blank group, and "###" represents that the p value is less than 0.001 relative to the blank group, "*" represents that the p value is less than 0.05 relative to the control group, "**" represents that the p value is less than 0.01 relative to the control group, and "***" represents that the p value is less than 0.001 relative to the control group.
[0078] See Figure 1 . As shown in Figure 1 , the control group shows that the oxidative damage simulation indeed induces the intracellular generation of a large amount of ROS, and the ROS content of the control group increases by 1262% relative to the blank group. In contrast, the ROS content of the experimental group is 1169%, which is decreased by 93% relative to the control group, so it can be known that Lactobacillus reuteri TCI979 can help cells effectively resist cell oxidative damage caused by hydrogen peroxide. It is known that high concentration of ROS can trigger oxidative stress, which can cause mitochondrial dysfunction, thereby damaging skeletal muscle cell components, and the increase of ROS can interfere with skeletal muscle differentiation and reduce the efficiency of myoblast generation.
[0079] Example 4: Apoptosis test
[0080] This test observes whether the sample can help cells avoid apoptosis under the condition that the cells are subjected to external oxidative damage simulated by hydrogen peroxide (H2O2). Here, the cells are stained with FITC-fluorescent Annexin V, and PI is used as a nuclear dye, and fluorescence microscopy or flow cytometry is used to detect apoptosis and the stage of apoptosis.
[0081] 4-1. Materials and instruments:
[0082] Cells: Human mononuclear cells (obtained from ATCC, TIB202, hereinafter referred to as THP-1 cells).
[0083] Culture medium: RPMI 1640 (Roswell Park Memorial Institute, purchased from Gibco), added with 10% FBS (Fetal Bovine Serum, purchased from Gibco) and 1% antibiotic-antimycotic (purchased from Gibco).
[0084] PBS buffer and DPBS buffer (purchased from Gibco).
[0085] Hydrogen peroxide H2O2 (purchased from Sigma).
[0086] Nucleus dye (Propidium iodide, PI, purchased from BD, Bioscience).
[0087] Annexin V, FITC Apoptosis Detection Kit (purchased from Enzo).
[0088] Flow cytometer (purchased from BD, model Accuri C6 Plus). TM
[0089] 4-2. Test procedure:
[0090] First, 1 x 10 5 THP-1 cells were implanted in a 24-well cell culture plate and incubated at 37°C, 5% CO2 for 24 hours. The THP-1 cells were separated into a blank group, a control group, and an experimental group.
[0091] Blank group: only medium was added and treated at 37°C for 2 hours.
[0092] Control group: only medium was added and treated at 37°C for 1 hour, then 1 mM hydrogen peroxide was added and treated at 37°C for another 1 hour.
[0093] Experimental group: medium containing 0.125% TCI979 sample prepared in Example 2 was added and treated at 37°C for 1 hour, then 1 mM hydrogen peroxide was added and treated at 37°C for another 1 hour.
[0094] The supernatant in the culture plate was removed and washed twice with 1 mL of 1X PBS solution. Then, PI dye and reagents in the test kit (Annexin V) were added to the cells in each group and treated at 37°C for 5 minutes.
[0095] After the cells in each group were transferred to a 1.5 mL centrifuge tube, centrifuged (400 x g) for 5 minutes, the supernatant was removed, washed with 1X PBS buffer, and then centrifuged (400 x g) for another 5 minutes. After centrifugation, the supernatant was removed, and 200 μL of 1X DPBS buffer was added to each tube to resuspend the PBMC cells, forming a test cell solution.
[0096] The fluorescence signals of FITC and PE in the test cell solution in each group were detected using a flow cytometer (excitation light: 450-490 nm; scattered light: 510-550 nm). The fluorescence intensity of the cells can reflect the apoptosis situation and be converted into a relative numerical value.
[0097] 4-3. Test results:
[0098] It is particularly noted that, Figure 2 The results of the experimental groups and the control group are converted into the performance of the blank group, with the quantitative results of the blank group being taken as 100. Among them, Student T-Test is used to analyze whether there is a statistically significant difference. In the figure, "#" represents p value less than 0.05 relative to the blank group, "##" represents p value less than 0.01 relative to the blank group, and "###" represents p value less than 0.001 relative to the blank group, "*" represents p value less than 0.05 relative to the control group, "**" represents p value less than 0.01 relative to the control group, and "***" represents p value less than 0.001 relative to the control group.
[0099] Please refer to Figure 2 As shown in Figure 2 , the control group shows that the oxidative damage simulation does indeed cause a large amount of apoptosis, and the number of apoptotic cells in the control group increases by 1201% relative to the blank group. In contrast, the number of apoptotic cells in the experimental group is 1122%, which is 79% lower than the control group. Therefore, Lactobacillus reuteri TCI979 can help cells effectively avoid apoptosis under external damage. That is, Lactobacillus reuteri TCI979 can alleviate cell apoptosis caused by oxidative stress, with an inhibition rate of 79%.
[0100] Example 5: Mitochondrial activity experiment in skeletal muscle cells
[0101] Mitochondria are important organelles for oxidative metabolism and energy production in cells. Poor mitochondrial function can lead to insufficient ATP production. Inactive and inefficient mitochondria are a kind of cell waste, and excessive accumulation of such waste can cause cell swelling and aging, leading to reduced muscle exercise tolerance. In this test, hydrogen peroxide (H2O2) is added to simulate the condition of cells being subjected to external oxidative damage, and the resulting low mitochondrial activity is measured. In this test, the lower the calculated low mitochondrial activity ratio, the better, indicating that Lactobacillus reuteri TCI979 can improve the metabolic rate of cells and reduce the aging phenomenon caused by waste accumulation.
[0102] 5-1. Materials and instruments:
[0103] Cell strain: Mouse myoblast C2C12 (hereinafter referred to as C2C12 cells) was used. C2C12 cells were purchased from the C2C12 cell strain (Cat. 60083) of the Bioresource Collection and Research Center (BCRC).
[0104] Culture medium: Dulbecco's modified Eagle's medium, purchased from Gibco, USA, Cat. 11965-092. Added 10% fetal bovine serum, purchased from Gibco, USA, Cat. 10437-028. Added 1% antibiotic-antimycotic, purchased from Gibco, USA, Cat. 15240-062.
[0105] Reagents: PBS buffer (purchased from Gibco, Cat. 14200-075), Trypan blue dead cell stain (purchased from Lonza, Cat. 17-942E), trypsin: 10X Trypsin-EDTA (purchased from Gibco), MitoScreen flow cytometry mitochondrial membrane potential assay kit (BD; Cat. BDB551302) including: JC-1 dye, 10X Assay buffer; hydrogen peroxide H2O2 (purchased from Sigma).
[0106] 5-2. Test procedure:
[0107] First, 1 x 10 5 C2C12 cells were taken to a six-well cell culture dish containing 2 mL of culture medium per well, and incubated at 37°C, 5% CO2, for 24 hours. The C2C12 cells were divided into three groups: experimental group, blank group, and control group.
[0108] Blank group: only added culture medium, incubated at 37°C, 5% CO2, for 25 hours.
[0109] Control group: added 1 mM of hydrogen peroxide, incubated at 37°C, 5% CO2, for 25 hours.
[0110] Experimental group: added 4% TCI979 sample prepared in Example 2 to the cell culture medium, incubated at 37°C, 5% CO2, for 24 hours. Then added 1 mM of hydrogen peroxide, and continued to incubate at 37°C, 5% CO2, for 1 hour.
[0111] The supernatant in the culture dish was removed and rinsed with 1 mL of 1X PBS solution twice. Then 200 μL of trypsin was added to each well and reacted for 5 minutes in the dark. After the reaction was completed, the cells in each well were collected into a corresponding individual 1.5 mL centrifuge tube, and the centrifuge tube containing the cells was centrifuged at 400 x g for 5 minutes. After centrifugation, the supernatant was removed, and the cells were resuspended with 1 mL of PBS solution, and the centrifuge tube containing the cells was again centrifuged at 400 x g for 5 minutes. After the second centrifugation, the supernatant in each centrifuge tube was removed, and 100 μL of JC-1 working reagent was added to each centrifuge tube and left to stand for 15 minutes in the dark. After 15 minutes, each centrifuge tube was centrifuged at 400 x g for 5 minutes. After centrifugation, the supernatant in each centrifuge tube was removed, and the cells were washed with 1 mL of buffer solution and centrifuged at 400 x g for 5 minutes, and this step was repeated twice. After the second centrifugation, the supernatant in each centrifuge tube was removed, and 500 μL of 1X PBS solution (with 2% FBS added) was added to each centrifuge tube to resuspend the cells to obtain the test cell solution. Finally, the fluorescence signal of each well of the test cell solution was measured by flow cytometry (excitation light: 488 nm; scattered light: 527 nm & 590 nm) to calculate the mitochondrial membrane potential of the cells for mitochondrial activity analysis.
[0112] 5-3. Test Results:
[0113] It should be noted that, Figure 3 The results are shown in relative ratios, i.e., the quantitative results of the blank group are taken as 100 to convert the quantitative results of the experimental and control groups into performance relative to the blank group. The Student T-Test was used to analyze whether there was a statistically significant difference. In the figure, “*” represents a p value less than 0.05 relative to the control group, “**” represents a p value less than 0.01 relative to the control group, and “***” represents a p value less than 0.001 relative to the control group.
[0114] Reference Figure 3 When the mitochondrial activity decrease measured for the blank group is taken as 100%, the mitochondrial activity decrease of the control group relative to the blank group is 173.5%. That is, the blank group shows normal (no external oxidative damage) conditions, and when the control group is added with hydrogen peroxide (H2O2) to simulate the situation where cells are subjected to external oxidative damage, the resulting mitochondrial activity decrease is significantly higher.
[0115] On the other hand, the mitochondrial activity decrease of the experimental group relative to the blank group is 73.1%, and it is a significant decrease of 100.4% compared to the control group. That is, Lactobacillus reuteri TCI979 can help cells effectively resist mitochondrial activity decrease caused by hydrogen peroxide, and restore the mitochondrial activity decrease caused by external oxidative damage.
[0116] Example 6: Telomerase activity test
[0117] Telomerase is a reverse transcriptase with an RNA segment, which is generally considered to repair the DNA of telomeres by reverse transcription, extend the length of telomeres, and maintain the integrity and stability of chromosomes. This test uses the ability of cells to maintain the length of telomeres to infer the influence on cell proliferation, senescence or potential stemness characteristics. The higher the telomerase activity, the stronger the ability to repair the DNA at the end of the chromosome.
[0118] 6-1. Materials and instruments:
[0119] Cells: Human chorionic mesenchymal cells (cbMSC-hTERT-RFP, BCRC, No. 60605, hereinafter referred to as mesenchymal cells).
[0120] Culture medium: 80% minimum essential medium (purchased from Eagle), added with 20% FBS (Fetal Bovine Serum, purchased from Gibco), 1% penicillin-streptomycin (purchased from Gibco), and 1 mM sodium pyruvate (purchased from Thermo Fisher) and 4 ng / mL human basic fibroblast growth factor (Basic Fibroblast Growth Factor, bFGF, purchased from Gibco, 13256-029).
[0121] PBS buffer and DPBS buffer (purchased from Gibco).
[0122] Flow cytometer (purchased from BD Company, model Accuri TM C6Plus).
[0123] 6-2. Test procedure:
[0124] First, 1 x 10 5 mesenchymal cells were planted in a 24-well cell culture plate and cultured at 37°C and 5% CO2 for 24 hours. After the mesenchymal cells in each well were grown, the mesenchymal cells were separated into a blank group and an experimental group.
[0125] Blank group: only add culture medium and culture at 37°C for three days.
[0126] Experimental group: add cell culture medium with a concentration of 0.125% TCI979 sample prepared in Example 2 and culture at 37°C for three days.
[0127] Next, the supernatant of each group of cells was removed, and the cells were washed twice with 1X PBS buffer. The interstitial cells were removed from the culture plate by adding trypsin and transferring them to a 1.5 mL centrifuge tube. A 2% fetal bovine serum neutralization reaction was added, and the cells were centrifuged (400 x g) for 5 minutes. The supernatant was removed after centrifugation, and the cells were washed again with 1X PBS buffer. The cells were again centrifuged (400 x g) for 5 minutes, and the medium was added to the centrifuge tube to resuspend the interstitial cells, which formed the test cell solution.
[0128] The red fluorescence signal in the test cell solution of each group was detected using a flow cytometer (wavelength set to 632-647 nm). The fluorescence intensity can reflect the telomerase activity state and be converted into a relative numerical value.
[0129] 6-3. Test results:
[0130] It should be noted that, Figure 4 The relative ratio is shown, i.e., the quantitative results of the blank group are taken as 100 to convert the quantitative results of the experimental and control groups into the performance relative to the blank group. Student T-Test is used to analyze whether there is a statistically significant difference. In the figure, “*” represents p value less than 0.05 relative to the blank group, “**” represents p value less than 0.01 relative to the blank group, and “***” represents p value less than 0.001 relative to the blank group.
[0131] Please refer to Figure 4 . As shown in Figure 4 , the relative telomerase activity of the experimental group is increased to 103.05% relative to the 100% of the blank group. It can be seen that Lactobacillus reuteri TCI979 can effectively increase the telomerase activity by 3.9% and slow down the rate of telomere shortening.
[0132] Example 7: Cell size and morphology test under natural aging
[0133] This test observes the effect of Lactobacillus reuteri on cell natural aging. Changes in cell size and morphology are one of the indicators for observing cell aging in vitro cell experiments. When the cell swells and the cell fibers increase, it represents that the cell aging is serious. Generally speaking, the main reason for cell natural aging is that cell division leads to shorter telomeres, and more active oxygen substances accumulate in the cell.
[0134] 7-1. Test materials and equipment description:
[0135] Cell strain: Human vascular endothelial cells (EA.hy926, hereinafter referred to as endothelial cells) were purchased from ATCC, CRL-2922.
[0136] Medium: 90% DMEM medium (Dulbecco's Modified Eagle Medium, brand: Gibco), 10% Fetal Bovine Serum (FBS, brand: Gibco), 1% Penicillin-streptomycin (brand: Gibco).
[0137] Reagent: Dulbecco's phosphate buffered saline (Gibco, hereinafter referred to as PBS), Trypsin.
[0138] Staining agent: ActinRed TM 555 ReadyProbes TM Reagent (Thermo; Cat. R37112), Hoechst 33342 (Thermo; Cat. 62249).
[0139] Equipment: Fluorescence microscope (brand ZEISS, Vert. Al), Flow cytometer (purchased from BD company, model Accuri TM C6 Plus).
[0140] 7-2. Test procedure:
[0141] First, with the cell number of 2 x 10 5 cells per well, endothelial cells were seeded in each well of a 6-well culture plate containing 2 mL of medium per well and incubated at 37°C for 24 hours, and then the cells were divided into blank and experimental groups.
[0142] Experimental group: incubated with medium containing 0.125% concentration of TCI979 sample prepared in Example 2, and incubated at 37°C for 7 days. The medium was changed every 2-3 days during the 7-day cell treatment.
[0143] Blank group: only medium was added, and incubated at 37°C for 7 days. The medium was changed every 2-3 days during the 7-day cell treatment.
[0144] First, trypsin was added to remove endothelial cells from the culture plate, and 4 / 5 of the cells were transferred to a 1.5 mL centrifuge tube. Each centrifuge tube was washed with DPBS to wash the endothelial cells, and then centrifuged (400 x g) for 5 minutes. After centrifugation, the supernatant was removed, 200 μL of DPBS was added to each centrifuge tube to resuspend the cells, and then the test cell solution was formed. Each test cell solution was measured using a flow cytometer. First, the cell size distribution was quantified, then the software was used to frame the large cell group in each group, and the percentage in the framing range was recorded. The results are shown in Figure 5shown.
[0145] The remaining 1 / 5 cells were seeded in a 24-well culture plate, and 1 drop of ActinRed 555 was added to each well TM 555ReadyProbes TM Reagent and 300 μL Hoechst 33342 (1:20,000 dilution) were added for staining, and the mixture was incubated in the dark for 15 minutes. The cells were observed and photographed under a fluorescence microscope in the dark, and the results are shown in FIG. 6. Figure 6
[0146] 7-3. Test results:
[0147] Here, Figure 5 The results are shown in relative ratios, i.e., the quantitative results of the experimental groups were converted into performance relative to the blank group by taking the quantitative results of the blank group as 100. Student T-Test was used to analyze whether there was a statistically significant difference. In the figures, "*" represents a p value less than 0.05 relative to the blank group, "**" represents a p value less than 0.01 relative to the blank group, and "***" represents a p value less than 0.001 relative to the blank group.
[0148] Reference Figure 5 The relative cell size of the experimental group was significantly reduced to 43.1% under the condition that the cell size of the blank group was taken as 100%. Thus, it can be seen that Lactobacillus reuteri TCI979 can effectively inhibit cell swelling and has the function of avoiding cell aging.
[0149] Reference Figure 6 As shown in FIG. 5, the same range of the selected frame was observed in the blank group and the experimental group. It can be seen that the number of nuclei in the blank group was less, the overall cell swelling was obvious, and the number of cell fibrous filaments was large. In contrast, the number of nuclei in the selected frame of the experimental group was large, the cells were in an elongated state and did not swell, and the number of cell fibrous filaments was small and dense. It can be seen that Lactobacillus reuteri can effectively inhibit cell swelling and inhibit excessive proliferation of cell fibrous filaments, and has the function of avoiding cell aging.
[0150] Example 8: Test of cell size and morphology under external oxidative damage
[0151] In this test, hydrogen peroxide (H2O2) was added to simulate the changes in cell size and morphology under external oxidative damage.
[0152] 8-1. Test materials and equipment description:
[0153] Cell strain: Human vascular endothelial cells (EA.hy926, hereinafter referred to as endothelial cells) were purchased from ATCC, CRL-2922.
[0154] Medium: 90% DMEM medium (Dulbecco's Modified Eagle Medium, brand: Gibco), 10% fetal bovine serum (Fetal Bovine Serum, brand: Gibco), 1% antibiotic (Penicillin-streptomycin, brand: Gibco).
[0155] Reagent: Phosphate buffer (Dulbecco's phosphate buffered saline brand Gibco, hereinafter referred to as PBS), trypsin, hydrogen peroxide H2O2 (purchased from Sigma).
[0156] Staining agent: ActinRed TM 555 ReadyProbes TM Reagent (Thermo; Cat. R37112), Hoechst 33342 (Thermo; Cat. 62249).
[0157] Equipment: Fluorescence microscope (brand ZEISS, Vert. Al), flow cytometer (purchased from BD company, model Accuri TM C6 Plus).
[0158] 8-2. Test procedure:
[0159] First, the endothelial cells were seeded in each well of a 6-well culture plate containing 2 mL of medium per well at a cell number of 2 x 10 5 cells per well, and incubated at 37°C for 24 hours, and then the cells were divided into a blank group, a control group and an experimental group.
[0160] Blank group: only medium was added, and treated at 37°C for 3 hours.
[0161] Control group: only medium was added, and treated at 37°C for 1 hour, then 30 μM of hydrogen peroxide cell culture medium was added, and treated at 37°C for 2 hours.
[0162] Experimental group: 0.125% TCI979 sample prepared in Example 2 was added to the cell culture medium, and treated at 37°C for 1 hour, then 30 μM of hydrogen peroxide was added, and treated at 37°C for 2 hours.
[0163] Next, trypsin was added to remove the endothelial cells from the culture dish and the cells were transferred to a 1.5 mL centrifuge tube. The endothelial cells in each centrifuge tube were washed with DPBS and centrifuged (400 x g) for 5 minutes. After centrifugation, the supernatant was removed and 200 μL of DPBS was added to each centrifuge tube to resuspend the cells to form the cell solution to be tested. The cell solution to be tested was measured using a flow cytometer. First, the cell size distribution was quantified. Then, the software was used to select the larger cell population in each group and record the percentage within the selected range. The results are shown in Figure 2. Figure 7 shown.
[0164] 8-3. Test results:
[0165] It should be noted that Figure 7 The data are presented as relative magnifications, assuming the blank group's quantitative results are 100 and converting the quantitative results of the experimental and control groups to relative to the blank group. The Student's t-test was used to analyze statistically significant differences. In the figures, "#" indicates a p-value of less than 0.05 for the control group relative to the blank group, "##" indicates a p-value of less than 0.01 for the control group relative to the blank group, and "###" indicates a p-value of less than 0.001 for the control group relative to the blank group. "*" indicates a p-value of less than 0.05 for the experimental group relative to the control group, "**" indicates a p-value of less than 0.01 for the experimental group relative to the control group, and "***" indicates a p-value of less than 0.001 for the experimental group relative to the control group.
[0166] refer to Figure 7 Taking the cell size of the blank group as 100%, the relative cell size of the control group cells under oxidative damage increased significantly to 119%, while the relative cell size of the experimental group decreased significantly to 93%. This indicates that Lactobacillus reuteri TCI979 can effectively resist cell aging caused by external oxidative damage. This indicates that Lactobacillus reuteri TCI979 can effectively inhibit cell swelling and prevent cell aging.
[0167] Example 9: Human testing
[0168] 9-1. Sample: Capsules prepared using the Lactobacillus reuteri powder prepared in Example 2, containing 100 mg of TCI979 powder.
[0169] 9-2. Subjects: 5 subjects, each of whom was 60 years old or older.
[0170] 9-3. Test items: blood malondialdehyde (MDA), total antioxidant capacity (TAC), sulfur compounds (f-Thiols), upper limb muscle endurance, and lower limb muscle endurance.
[0171] Among them, blood malondialdehyde (MDA), total antioxidant capacity (TAC), sulfur compounds (f-Thiols) are measured after blood by the commission of the medical laboratory.
[0172] Among them, the test method of upper limb muscle endurance: each subject uses the number of times of lifting dumbbells in 30 seconds with the usual hand, wherein lifting dumbbells refers to the state of hand elbow bending and straightening while holding the dumbbell with the palm, and the dumbbell used for women is 5 pounds and for men is 8 pounds.
[0173] Among them, the test method of lower limb muscle endurance: each subject stands up and sits down from the chair in 30 seconds.
[0174] 9-4. Test procedure:
[0175] Five subjects take 100 mg of the capsule prepared from the Lactobacillus reuteri powder in Example 2 every day, and continue to take for eight weeks. The measurement is carried out before the start of intake (i.e. week 0, also known as the blank group), after four weeks of drinking (i.e. week 4, also known as experimental group A), and after eight weeks of drinking (i.e. week 8, also known as experimental group B).
[0176] Blood malondialdehyde, total antioxidant capacity and sulfur compounds are calculated according to the values in the report provided by the medical laboratory, and the average values of the five subjects are presented.
[0177] The upper limb muscle endurance and lower limb muscle endurance test results are based on week 0, and the fourth week and the eighth week are presented in relative multiples, that is, the quantitative results of week 0 are taken as 100% to convert the quantitative results of the fourth week and the eighth week into relative percentages, so as to more clearly present the improvement status of each test item from the start to the end of the test.
[0178] 9-5. Test results:
[0179] Please refer to Figure 8 Under the condition of taking 100 mg of Lactobacillus reuteri every day and maintaining daily diet and routine, the average blood malondialdehyde (MDA) concentration of the five subjects decreased significantly from 1.52 mmol / L (blank group) to 1.17 mmol / L (experimental group A) after four weeks of intake, and although it adjusted slightly to 1.28 mmol / L (experimental group B) after eight weeks of intake, the overall trend of decrease after taking Lactobacillus reuteri TCI979 can still be seen. Among them, the blood malondialdehyde (MDA) concentration of the five subjects all decreased, that is, the proportion of improved people reached 100%. It can be observed that the average blood malondialdehyde difference before and after using the Lactobacillus reuteri of the invention for only eight weeks reached 15.8%. That is, taking 100 mg of Lactobacillus reuteri every day can effectively reduce the blood malondialdehyde concentration in the blood and improve the antioxidant capacity.
[0180] Referring to Figure 9 With the daily intake of 100 mg of Lactobacillus reuteri and the maintenance of daily diet and routine, the average total antioxidant capacity (TAC) of 5 subjects rose from 0.56 (blank group) to 0.60 (experimental group A) after four weeks of intake, and was stably maintained at 0.60 (experimental group B) after eight weeks of intake, and it can be seen that the overall trend of the intake of Lactobacillus reuteri TCI979 showed an upward trend. Among them, 3 out of 5 subjects showed an increase in total antioxidant capacity, that is, the proportion of improved people reached 60%. It can be observed that the difference in average blood total antioxidant capacity before and after using the Lactobacillus reuteri of the present application for only eight weeks reached 7.1%. That is, the daily intake of 100 mg of Lactobacillus reuteri can effectively improve the antioxidant capacity.
[0181] Referring to Figure 10 With the daily intake of 100 mg of Lactobacillus reuteri and the maintenance of daily diet and routine, the average total antioxidant capacity (TAC) of 5 subjects rose from 0.56 (blank group) to 0.60 (experimental group A) after four weeks of intake, and was stably maintained at 0.60 (experimental group B) after eight weeks of intake, and it can be seen that the overall trend of the intake of Lactobacillus reuteri TCI979 showed an upward trend. Among them, 3 out of 5 subjects showed an increase in total antioxidant capacity, that is, the proportion of improved people reached 60%. It can be observed that the difference in average blood total antioxidant capacity before and after using the Lactobacillus reuteri of the present application for only eight weeks reached 7.1%. That is, the daily intake of 100 mg of Lactobacillus reuteri can effectively improve the antioxidant capacity.
[0182] Referring to Figure 11 With the daily intake of 100 mg of Lactobacillus reuteri and the maintenance of daily diet and routine, the average total antioxidant capacity (TAC) of 5 subjects rose from 0.56 (blank group) to 0.60 (experimental group A) after four weeks of intake, and was stably maintained at 0.60 (experimental group B) after eight weeks of intake, and it can be seen that the overall trend of the intake of Lactobacillus reuteri TCI979 showed an upward trend. Among them, 3 out of 5 subjects showed an increase in total antioxidant capacity, that is, the proportion of improved people reached 60%. It can be observed that the difference in average blood total antioxidant capacity before and after using the Lactobacillus reuteri of the present application for only eight weeks reached 7.1%. That is, the daily intake of 100 mg of Lactobacillus reuteri can effectively improve the antioxidant capacity.
[0183] Referring to Figure 12In the case of daily intake of 100 mg of Lactobacillus reuteri and maintaining the daily diet and routine, the average lower limb muscle endurance of the 5 subjects increased from 100% (blank group) to 129.0% (experimental group A) after four weeks of intake, and continuously increased to 151.5% (experimental group B) after eight weeks of intake, and it was observed that the overall trend of the Lactobacillus reuteri TCI979 was significantly increased. Among them, 4 out of 5 subjects showed a significant increase in lower limb muscle endurance, that is, the proportion of improved people reached 80%. It was observed that the average lower limb muscle endurance difference before and after using the Lactobacillus reuteri of the present application for only eight weeks reached 51.5%. That is, daily intake of 100 mg of Lactobacillus reuteri can effectively improve the lower limb muscle endurance.
[0184] In summary, the Lactobacillus reuteri and / or metabolites thereof of any embodiment can reduce the content of malondialdehyde in blood, improve the total antioxidant capacity or the content of sulfur compounds in blood, inhibit the content of active oxygen or reduce cell apoptosis, thereby slowing down muscle loss. The Lactobacillus reuteri and / or metabolites thereof of any embodiment can improve muscle cell mitochondrial activity, reduce the content of malondialdehyde in blood, improve the total antioxidant capacity or the content of sulfur compounds in blood, or inhibit the content of active oxygen, thereby improving muscle endurance. The Lactobacillus reuteri and / or metabolites thereof of any embodiment can slow down the rate of telomere shortening, improve telomerase activity, or inhibit the content of active oxygen, thereby slowing down cell aging.
[0185] Of course, the present application can have other various embodiments, and those skilled in the art can make various corresponding changes and modifications according to the present application without departing from the spirit and essence of the present application, but these corresponding changes and modifications should all belong to the protection scope of the claims of the present application.
Claims
1. Use of Lactobacillus reuteri and / or metabolites thereof for the manufacture of a composition for slowing down muscle loss, wherein the Lactobacillus reuteri is Lactobacillus reuteri having the deposit accession number DSM 34539.
2. Use according to claim 1, wherein the Lactobacillus reuteri and / or metabolites thereof are for reducing the level of malondialdehyde in blood.
3. Use according to claim 1, wherein the Lactobacillus reuteri and / or metabolites thereof are for increasing the total antioxidant capacity (TAC) or the level of f-Thiols in blood.
4. Use according to claim 1, wherein the Lactobacillus reuteri and / or metabolites thereof are for inhibiting the level of reactive oxygen species.
5. Use according to claim 1, wherein the Lactobacillus reuteri and / or metabolites thereof are for reducing apoptosis.
6. Use of Lactobacillus reuteri and / or metabolites thereof for the manufacture of a composition for increasing muscle endurance, wherein the Lactobacillus reuteri is Lactobacillus reuteri having the deposit accession number DSM 34539.
7. Use according to claim 6, wherein the Lactobacillus reuteri and / or metabolites thereof are for increasing mitochondrial activity in muscle cells.
8. Use according to claim 6, wherein the Lactobacillus reuteri and / or metabolites thereof are for reducing the level of malondialdehyde in blood.
9. Use according to claim 6, wherein the Lactobacillus reuteri and / or metabolites thereof are for increasing the total antioxidant capacity (TAC) or the level of f-Thiols in blood.
10. Use according to claim 6, wherein the Lactobacillus reuteri and / or metabolites thereof are for inhibiting the level of reactive oxygen species.
11. Use of Lactobacillus reuteri and / or metabolites thereof for the manufacture of a composition for slowing down cellular aging, wherein the Lactobacillus reuteri is Lactobacillus reuteri having the deposit accession number DSM 34539.
12. Use according to claim 11, wherein the Lactobacillus reuteri and / or metabolites thereof are for slowing down the rate of telomere shortening.
13. Use according to claim 12, wherein the Lactobacillus reuteri and / or metabolites thereof are for increasing the activity of telomerase.
14. Use according to claim 11, wherein the Lactobacillus reuteri and / or metabolites thereof are for inhibiting the level of reactive oxygen species.
